Cyclerion Therapeutics Collaborates With Medsteer To Integrate Medsteer's Technology Into Cyclerion's CYC-126 Program

Cyclerion Therapeutics, Inc. (NASDAQ:CYCN), a biopharmaceutical company pioneering neuropsychiatric therapies, today announced an application-specific, exclusive collaboration with Medsteer, a leader in anesthetic delivery systems driven by real-time patient feedback. The new collaboration agreement expands upon the parties' existing development collaboration and is intended to enable the integration of Medsteer's proprietary technology and know-how into Cyclerion's lead program, CYC-126.

CYC-126 is a potentially novel anesthetic-based investigational therapy that incorporates real-time patient feedback and is currently being developed for the treatment of treatment-resistant depression ("TRD"). CYC-126 is being designed as an individualized, precision-delivered treatment that leverages well-characterized anesthetic agents in combination with real-time EEG monitoring and algorithm-guided dosing. Cyclerion believes this approach has the potential to enable clinicians to more precisely guide patients toward targeted brain states that may be associated with antidepressant effects, addressing a significant unmet need among patients with TRD who are looking for alternative therapies.